Largactil 25 mg, 100 mg Tablets.
PDF Leaflet Revision Date: 14 October 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Management of psychotic conditions and manic phase of bipolar disorder.
Dosage (summary)
Initial: 25-50 mg three times daily; elderly: 1/3 to 1/2 normal dose.
Special Populations
- Elderly
- Debilitated patients
Pregnancy & Breastfeeding
Not recommended during pregnancy; may be excreted in breast milk.
Key Drug Interactions
- CYP1A2 inhibitors
- Amitriptyline
- QT-prolonging medicines
Contraindications
- Hypersensitivity to chlorpromazine
- CNS depression
- QT prolongation
Common side effects
- Drowsiness
- Hypotension
- Extrapyramidal symptoms
Counselling Points
- Avoid abrupt withdrawal
- Monitor for signs of liver toxicity
- Caution with CNS depressants
Serious warnings
- Increased risk of cerebrovascular events in elderly
- Severe liver toxicity
- Venous thromboembolism risk
Important Disclaimer
The Largactil 25 mg, 100 mg Tablets. professional information leaflet below is the property of Sanofi-Aventis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
